INFLAMMATORY BOWEL DISEASES IN CHILDREN: PECULIARITIES OF THE DISEASE COURSE AND THERAPY

Abstract

The article is devoted to one of the most serious and unsolved issues in current gastroenterology: the issue of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn’s disease (CD). IBD is a chronic, relapsing inflammatory condition of the gastrointestinal tract (GIT) (often the intestine), resulting in irreversible disruption of its structure and functions, which disables the patient. At an early age, patients have a greater lesion site, but at the same time, less specific, inapparent clinical signs, the effect of the disease on the physical and sexual development of the child. This review presents current knowledge on the epidemiology, aetiology and key points of current concepts of pathogenesis, symptomatology and therapy. The prescription of drugs for the correction of microbiocenosis in the combination therapy of IBD positively affects the clinical and endoscopic course of the disease, effectively relieving exacerbations and maintaining remission. It also improves the safety of treatment and enhances the quality of life of patients. S. boulardii-based drugs showed high efficacy and safety in several studies, which is associated with their probiotic activity against opportunistic microorganisms and clostridia, and with immunomodulating action.

Keywords

• inflammatory bowel disease
• ulcerative colitis
• crohn’s disease
• intestinal microbiota
• diarrhea
• s. boulardii